ResMed (RMD) In-Depth Stock Report
The leader in sleep apnea devices and masks, priced on recurring resupply revenue and the effect of obesity drugs on demand.
Investment Summary
Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.
- Obesity drugs expand diagnosis and lead to more patients.
- Recurring resupply grows steadily.
- Gross margins improve.
- Digital tools improve adherence.
- ResMed leads in sleep apnea devices and masks.
- Recurring resupply and high margins define the model.
- Obesity drug effects are the main debate.
- Device unit growth and mask resupply are the key numbers.
- ResMed makes CPAP machines, masks, and software for sleep apnea and respiratory care.
- Masks and accessories are replaced regularly, creating recurring resupply revenue.
- The addressable market is large because most sleep apnea remains undiagnosed.
- GLP-1 obesity drugs raise questions about long-term demand for sleep apnea devices.
- The equity debate is whether obesity drugs shrink or expand the market.
Executive Summary
ResMed benefits from an installed base of patients who need ongoing masks and supplies, giving revenue high visibility.
Digital platforms connect devices and help providers manage patients, improving adherence and outcomes.
Obesity drugs could reduce sleep apnea severity for some patients, but they could also lead more people into the health system and to diagnosis.
Margins are high due to scale, and the company has been improving gross margin after supply chain normalization.
The realistic thesis: a high-margin, recurring-revenue device leader whose valuation is sensitive to the debate on obesity drugs.
Industry & Market Backdrop
The broader competitive and macro environment RMD operates in — context a pure valuation table can't convey on its own.
Sleep apnea is widely underdiagnosed, and awareness is rising through wearables and consumer tests.
GLP-1 drugs have altered sentiment around sleep apnea demand.
Reimbursement and competition from a rival manufacturer's recall boosted market share earlier.
Digital health integration is becoming important for adherence.
Aging demographics and obesity prevalence support long-term demand.
Live Key Statistics
Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/RMD. Fields the pipeline doesn't return this load are omitted rather than shown blank.
Business Overview
Sleep and respiratory care devices such as CPAP and bilevel machines.
Masks and accessories with regular replacement cycles.
Software for out-of-hospital care management.
A global distribution network including home medical equipment suppliers.
Segment Deep Dive
A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.
CPAP and related machines are the entry point for patients. Placement grows the installed base for recurring revenue.
Recurring resupply provides high-margin, predictable revenue. Coverage and patient compliance drive volume.
Software for care management and out-of-hospital solutions adds recurring revenue and integration. It is smaller but strengthens ecosystem stickiness.
Capital Allocation & Balance Sheet Philosophy
How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.
Free cash flow funds dividends, buybacks, and bolt-on acquisitions.
Leverage is modest and has been reduced.
Investment in research targets connected devices and software.
Capital return is consistent.
Management & Governance
Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.
Leadership has emphasized a 2030 vision to help more people with sleep and respiratory conditions.
Management provides gross margin and growth guidance.
Governance is conventional; review the proxy for details.
Communication on GLP-1 effects is a management test.
See exactly how we get RMD's fair-value range
| Method | Relevance | Implied Value |
|---|---|---|
| Our DCF Model | High | |
| Our P/E Based | Medium | |
| Our Book Value Based | Medium | |
| Graham Number | Medium | |
| PEG Ratio Based | Low | |
| ROIC Based | Medium | |
| FCF Yield Based | High |
Forecast Revenue and Free Cash Flow
5-Year Monte Carlo Simulation
Included with a subscription or a one-time purchase of this ResMed report:
- Fair value from 7 methods, weighted by relevance to this business
- 5-year financial forecast and DCF/earnings sensitivity grids
- Decomposed AI Score, Monte Carlo simulation, and institutional/analyst data
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
Bull Case vs. Bear Case
- Obesity drugs expand diagnosis and lead to more patients.
- Recurring resupply grows steadily.
- Gross margins improve.
- Digital tools improve adherence.
- Market share gains persist.
- GLP-1 drugs reduce new starts and adherence.
- Competitors regain share.
- Reimbursement pressure appears.
- Growth slows.
- Margins compress.
Related Reports
In-depth reports for other names in ResMed's comparable set.
4 catalysts and 4 risks we're tracking for RMD
| Catalyst | Expected Impact | Timeframe |
|---|---|---|
Included with a subscription or a one-time purchase of this ResMed report:
- Catalyst list, each tagged with expected impact and timing
- Risk register scored by probability and severity
- 4 key metrics to watch before the next earnings report
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
What Would Change Our Mind?
Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.
- New starts remain strong despite GLP-1 adoption
- Gross margin expands
- Digital adoption lifts adherence
- New starts decline
- Adherence falls
- Competitors regain share
Competitive Positioning
ResMed's moat is brand, installed base, clinical evidence, and digital ecosystem.
Philips, Fisher and Paykel Healthcare, and others compete in devices and masks.
Patients are sticky to mask fit and familiarity.
The vulnerability is demand impact from obesity therapy and competitive reentry.
Investor Decision Framework
A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.
- Own it if you want a recurring-revenue medtech leader and believe obesity drugs are manageable.
- Skip it if you fear demand disruption.
- Track unit growth and resupply trends.
The BriMindInvest Edge
Why this report is different from asking a general-purpose AI chatbot about the stock.
- Every valuation number on this page is computed live from current market data through our own DCF, scoring, and Monte Carlo engines — not summarized or paraphrased from other analysts' reports the way a general chatbot would.
- The relevance-weighted fair value, reverse-DCF market-implied growth, fundamentals-based Monte Carlo, and scenario tables above are proprietary calculations you cannot get by asking a general-purpose AI for "RMD fair value" — those answers come from web summaries of other people's price targets, not a live, disclosed-assumption model.
- Our 1-year price-target model has a real, published backtest (see Model Track Record above where covered) — we show our work and our error rate rather than asserting accuracy.
- Numbers here are refreshed every time you load the page, not cached from a training cutoff months or years in the past.
Data Sources & Methodology
Valuation, price, and financial-statistics data in this report are fetched live from our production market-data pipeline (Yahoo Finance and Finnhub) at the time you loaded this page. The AI Score is a percentile ranking against our full covered stock universe, recomputed nightly. The fundamentals-based Monte Carlo and Bull/Base/Bear scenarios randomize growth rate, discount rate, and terminal growth around the same disclosed DCF assumptions used in the valuation table — they are not derived from resampled historical stock returns. The secondary historical-volatility simulation (2,000 bootstrap paths, seeded for reproducibility) uses the stock's own historical monthly returns and is shown separately because it measures a different thing (volatility) than the fundamentals-based model (intrinsic value).
This report is for informational and educational purposes only and does not constitute financial, investment, or tax advice, or a recommendation to buy or sell any security. All valuation models, price targets, and simulations are estimates based on historical and current data; actual results will differ, potentially substantially. Investing involves risk, including loss of principal. See our full Methodology and Disclaimer.
Free vs. Premium: What You're Getting
- Narrative overview and general bull/bear framing
- Headline price and basic company facts
- No live valuation model, AI Score, or forecast table
- Relevance-weighted fair value range and reverse-DCF market-implied growth
- 5-year financial forecast, DCF sensitivity grid, and Bull/Base/Bear scenario table
- Fundamentals-based Monte Carlo and decomposed AI Score with sub-factor components
- Real, published backtested accuracy where RMD is in our coverage set
Glossary of Key Terms
Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.
Frequently Asked Questions
Unlock Full AI-Powered Analysis
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.